Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature
Covering: 1988 to 2012 This review presents recommended nomenclature for the biosynthesis
of ribosomally synthesized and post-translationally modified peptides (RiPPs), a rapidly …
of ribosomally synthesized and post-translationally modified peptides (RiPPs), a rapidly …
Biomaterials based on chitin and chitosan in wound dressing applications
Wound dressing is one of the most promising medical applications for chitin and chitosan.
The adhesive nature of chitin and chitosan, together with their antifungal and bactericidal …
The adhesive nature of chitin and chitosan, together with their antifungal and bactericidal …
Biomedical applications of chitin and chitosan based nanomaterials—A short review
… SV Nair is also grateful to DST, India, which partially supported this work, under a center
grant of the Nanoscience and Nanotechnology Initiative program monitored by Dr. CNR Rao. …
grant of the Nanoscience and Nanotechnology Initiative program monitored by Dr. CNR Rao. …
On the opportunities and risks of foundation models
…, S Mirchandani, E Mitchell, Z Munyikwa, S Nair… - arXiv preprint arXiv …, 2021 - arxiv.org
AI is undergoing a paradigm shift with the rise of models (eg, BERT, DALL-E, GPT-3) that are
trained on broad data at scale and are adaptable to a wide range of downstream tasks. We …
trained on broad data at scale and are adaptable to a wide range of downstream tasks. We …
AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models
The AlphaFold Protein Structure Database (AlphaFold DB, https://alphafold.ebi.ac.uk ) is an
openly accessible, extensive database of high-accuracy protein-structure predictions. …
openly accessible, extensive database of high-accuracy protein-structure predictions. …
[HTML][HTML] First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
…, S Nair, R Juergens, S Peters… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label …
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label …
Factors predicting the use of technology: findings from the Center for Research and Education on Aging and Technology Enhancement (CREATE).
…, N Charness, AD Fisk, C Hertzog, SN Nair… - Psychology and …, 2006 - psycnet.apa.org
The successful adoption of technology is becoming increasingly important to functional
independence. The present article reports findings from the Center for Research and Education …
independence. The present article reports findings from the Center for Research and Education …
[HTML][HTML] Structural mechanism for rifampicin inhibition of bacterial RNA polymerase
…, N Korzheva, A Mustaev, K Murakami, S Nair… - Cell, 2001 - cell.com
Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial
pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of …
pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of …
[HTML][HTML] SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function
Although animal models have been evaluated for severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection, none have fully recapitulated the lung disease phenotypes …
2 (SARS-CoV-2) infection, none have fully recapitulated the lung disease phenotypes …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
…, LT Campos, DR Gandara, BP Levy, SG Nair… - The lancet …, 2015 - thelancet.com
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …